Scarica l'app Stockscreener
308.87
2.64%
-8.125
Precedente Chiudi:
$316.99
Aprire:
$305.5
Volume 24 ore:
115.54K
Relative Volume:
0.42
Capitalizzazione di mercato:
$34.25B
Reddito:
$4.98B
Utile/perdita netta:
$69.60M
Rapporto P/E:
594.20
EPS:
0.5198
Flusso di cassa netto:
$525.67M
1 W Prestazione:
-16.73%
1M Prestazione:
-10.54%
6M Prestazione:
-7.05%
1 anno Prestazione:
+13.55%
Intervallo 1D:
$304.62
$311.74
Intervallo di 1 settimana:
$304.62
$372.73
Portata 52W:
$196.45
$385.22
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Nome
Beone Medicines Ltd Adr
Settore
Industria
Telefono
41-616851900
Indirizzo
C/O BEONE MEDICINES I GMBH, BASEL
Compare ONC vs VRTX, REGN, ARGX, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
309.55 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.02 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.33 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
759.53 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.32 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-09-18 | Iniziato | Barclays | Overweight |
| 2025-04-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-03-03 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-12-03 | Ripresa | Morgan Stanley | Overweight |
| 2024-09-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-02-06 | Ripresa | JP Morgan | Overweight |
| 2023-09-12 | Iniziato | Macquarie | Outperform |
| 2023-08-17 | Iniziato | Jefferies | Buy |
| 2023-07-17 | Iniziato | Citigroup | Buy |
| 2023-06-30 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | Iniziato | Daiwa Securities | Buy |
| 2022-10-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-10-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | Ripresa | JP Morgan | Overweight |
| 2022-03-17 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | Iniziato | Deutsche Bank | Buy |
| 2021-10-12 | Iniziato | Bernstein | Outperform |
| 2021-10-06 | Aggiornamento | CLSA | Underperform → Buy |
| 2021-03-08 | Iniziato | China Renaissance | Buy |
| 2021-03-01 | Downgrade | CLSA | Outperform → Underperform |
| 2020-11-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | Downgrade | Maxim Group | Buy → Hold |
| 2020-11-06 | Downgrade | Piper Sandler | Neutral → Underweight |
Mostra tutto
Beone Medicines Ltd Adr Borsa (ONC) Ultime notizie
BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment - Finviz
Artisan Partners Limited Partnership Reduces Position in BeOne Medicines Ltd. – Sponsored ADR $ONC - Defense World
Generali Investments Management Co LLC Takes Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Here's What Important Indicators Reveal About BeOne Medicines Ltd.Sponsored ADR (ONC) Fourth Quarter Results - Bitget
Here's What Key Metrics Tell Us About BeOne Medicines Ltd.Sponsored ADR (ONC) Q4 Earnings - Nasdaq
BeOne Medicines Ltd.Sponsored ADR $ONC Stock Holdings Decreased by Primecap Management Co. CA - MarketBeat
What's Driving the Market Sentiment Around BeOne Medicines Ltd? - Sahm
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
M&G PLC Has $41.17 Million Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
ABN Amro Investment Solutions Lowers Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Bernstein Remains a Buy on BeOne Medicines AG (ONC) - Finviz
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026 - GlobeNewswire Inc.
Candriam S.C.A. Sells 67,718 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Chan Henry Lee Sells 1,660 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines Trial Wins And Sonrotoclax Clearance Meet Valuation Discount - Sahm
3 Stocks to Buy in February - Finviz
Wall Street Bullish on BeOne Medicines AG (ONC) amid Robust Pipeline Development - Finviz
Mirae Asset Global Investments Co. Ltd. Acquires 38,992 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Citizens Highlights BeOne Medicines' (ONC) $3.8B Revenue Potential for 2025 - Finviz
BeOne Medicines Collaboration Extends Safety Modeling As Shares Trade Below Targets - Sahm
Assessing BeOne Medicines (ONC) Valuation After Expanded InSysBio Collaboration On Clinical Trial Modeling - Sahm
Did BeOne’s New Uptrend And Upgraded Earnings Outlook Just Shift Its (ONC) Investment Narrative? - simplywall.st
EMCOR Group, Inc. (NYSE:EME) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Financial Review: Atossa Genetics (NASDAQ:ATOS) versus ADM Tronics Unlimited (OTCMKTS:ADMT) - Defense World
BeOne Medicines (NASDAQ:ONC) Shares Gap DownShould You Sell? - MarketBeat
BeOne Medicines Earnings Momentum Spurs Valuation Debate And Analyst Optimism - Sahm
Five Below Upgraded, Spotify Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BEONE MEDICINES LTD-ADR (NASDAQ:ONC) Passes Minervini Trend Template and Strong Growth Scan - ChartMill
CICC Predicts HSI to Add ZIJIN GOLD INTL/ BEONE MEDICINES/ PICC P&C/ AKESO as New Constituents; STANCHART May Replace HANG SENG BANK - AASTOCKS.com
Assessing BeOne Medicines (ONC) Valuation After A Year Of Strong Shareholder Returns - Sahm
HERIZON-GEA-01 Phase 3 Zanidatamab Combo Data Might Change The Case For Investing In BeOne Medicines (ONC) - Sahm
Chan Henry Lee Sells 664 Shares of BeOne Medicines (NASDAQ:ONC) Stock - Defense World
JGP Global Gestao de Recursos Ltda. Decreases Stock Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Fingerlakes Wealth Management Inc. Has $6.96 Million Holdings in Schwab U.S. Large-Cap Growth ETF $SCHG - Defense World
BeOne Medicines (NASDAQ:ONC) SVP Chan Henry Lee Sells 664 Shares - MarketBeat
Snowline Gold (CVE:SGD) Shares Up 3% – Here’s What Happened - Defense World
Is the Options Market Predicting a Spike in BeOne Medicines Stock? - Yahoo Finance
BrightSpire Capital (NYSE:BRSP) Shares Gap Down – Here’s What Happened - Defense World
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Voya Investment Management LLC Raises Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
John Oyler Sells 75,631 Shares of BeOne Medicines (NASDAQ:ONC) Stock - Defense World
BeOne Medicines appoints Dr. Lai Wang as president and global head of R&D - Investing.com
Beone Medicines Ltd Adr Azioni (ONC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Beone Medicines Ltd Adr Azioni (ONC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lee Chan Henry | SVP, General Counsel |
Feb 04 '26 |
Sale |
349.52 |
1,660 |
580,197 |
0 |
1.58%
0.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):